Thanks to Chronicle of Philanthropy for this:
For decades, philanthropy played an unusually important role in keeping psychedelic science alive when governments, major foundations and pharmaceutical companies largely stayed away. Now, as psychedelic medicines move closer to mainstream acceptance, the role of donors may be changing.
A recent Chronicle of Philanthropy report highlights a significant transition underway in psychedelic funding. Philanthropic capital is expanding beyond early clinical research and increasingly supporting the infrastructure that could be necessary for psychedelic medicine to function within the broader healthcare system.
That includes advocacy, patient access, healthcare-system preparation, professional education, public safety and research into new therapeutic applications.
The shift raises a larger question for the field: What should philanthropy fund once psychedelic medicine is no longer considered a fringe scientific pursuit?
From De-Risking Psychedelic Science to Building a Field
Private philanthropy helped finance some of the foundational psychedelic research that traditional institutions considered too controversial or speculative.
That early support ultimately helped “de-risk” the field. Today, governments are investing substantial public resources, biotechnology companies are advancing psychedelic drugs through clinical development, and major pharmaceutical companies are entering the sector.
One of the clearest examples is AtaiBeckley. Its scientific lineage includes work associated with the nonprofit Beckley Foundation, one of the longstanding supporters of psychedelic research. Eli Lilly’s $2.8 billion agreement to acquire AtaiBeckley illustrates just how dramatically the commercial landscape has changed.
As conventional investment becomes increasingly capable of financing late-stage drug development, philanthropy’s greatest value may shift toward areas that pharmaceutical companies have little economic incentive to support.
Those opportunities are becoming increasingly diverse.
The Major Players in Psychedelic Philanthropy
The Chronicle identifies a growing network of wealthy individuals, foundations and philanthropic organizations supporting psychedelic science and implementation.
The Steven & Alexandra Cohen Foundation is among the largest. It has contributed more than $69 million toward psychedelic research and has also supported education and workforce development.
Another particularly important organization is the Psychedelic Science Funders Collaborative (PSFC). According to co-founder Joe Green, its network of more than 100 members has directed more than $100 million toward psychedelic initiatives over nine years.
That makes PSFC an important nexus in the emerging psychedelic philanthropic ecosystem.
The Effie and Wofford Cain Foundation, through Charmaine and Gordon McGill, made a $12.5 million naming gift in 2024 to establish the Center for Psychedelic Research and Therapy at Dell Medical School at the University of Texas at Austin.
The McGills’ involvement also illustrates something distinctive about psychedelic philanthropy: many of its largest supporters have deeply personal reasons for entering the field. Charmaine McGill lost one son to suicide and another to a fentanyl overdose and has spoken about her own experience with psychedelic therapies.
Steve and Genevieve Jurvetson, through the Jurvetson Foundation, represent another potentially important direction for philanthropic research.
Their interests are moving beyond the familiar depression and PTSD indications. The foundation helped support Stanford research involving ibogaine treatment for veterans with traumatic brain injuries and is backing Johns Hopkins research investigating whether psilocybin could help stroke patients regain motor function.
The Jurvetsons are also interested in potential applications involving Alzheimer’s and Parkinson’s disease.
Genevieve Jurvetson told the Chronicle that while they intend to continue funding research, the threshold for doing so is becoming considerably higher.
That sentiment may foreshadow a broader change in psychedelic philanthropy.
The Next Frontier May Not Be Another Depression Trial
Depression, PTSD and addiction have understandably dominated psychedelic research.
But as evidence accumulates and commercial drug-development programs mature, philanthropic funders may increasingly look toward scientific questions that remain too speculative for conventional investors.
Several possibilities are already emerging:
stroke recovery → neurodegenerative diseases → women’s health → addiction and traumatic brain injury → implementation science → psychedelic safety
Research into neuroplasticity may become especially important.
Psychedelic research is increasingly intersecting with the broader field of psychoplastogens — compounds capable of promoting structural and functional neural plasticity.
Over time, the philanthropic conversation could therefore expand from funding “psychedelic therapy” specifically toward funding research into therapeutically useful neuroplasticity more broadly.
That could eventually include both psychedelic compounds and drugs designed to produce some of their neuroplastic effects without a prolonged hallucinogenic experience.
How $300,000 Helped Unlock Tens of Millions in Texas
One of the most striking examples of philanthropic leverage comes from Texas.
According to Logan Davidson, senior adviser and founding executive director of Texans for Greater Mental Health, his organization, Veterans Exploring Treatment Solutions and others spent slightly more than $300,000 advocating for legislation supporting psychedelic research.
Texas subsequently committed $50 million to psychedelic research.
Advocates also believe the political momentum generated in Texas contributed to subsequent federal action directing another $50 million toward research.
The relationship shouldn’t be interpreted as a simple dollar-for-dollar causal equation. But it demonstrates something important about an emerging field: relatively small amounts of philanthropic capital can sometimes produce disproportionately large effects when used to build evidence, organize constituencies and influence public policy.
Veterans have been particularly influential.
Veterans and the Rise of Ibogaine
Veterans Exploring Treatment Solutions (VETS) funds psychedelic treatment for more than 300 veterans annually and is participating in policy advocacy across 31 states.
Many veterans seeking ibogaine treatment currently travel outside the United States because the drug remains federally controlled.
Veterans who report significant improvements following psychedelic treatment have increasingly become advocates themselves, speaking with lawmakers and helping overcome some of the political stigma historically associated with psychedelics.
That has helped create one of the more unusual political dynamics surrounding psychedelic medicine: substantial interest from both progressive psychedelic advocates and conservative lawmakers focused on veterans, suicide, traumatic brain injury and opioid addiction.
Ibogaine may consequently become one of the most politically consequential areas of psychedelic research over the next several years.
Preparing Hospitals for Psychedelic Medicine
FDA approval, whenever it arrives, will not by itself create a functioning psychedelic healthcare system.
Hospitals and healthcare providers would immediately confront practical questions.
Who supervises patients during treatments lasting several hours? What roles should psychiatrists, nurses, psychologists and therapists play? What facilities are required? How should adverse events be handled? Will Medicare, Medicaid and commercial insurers cover treatment? And how can psychedelic therapies reach rural and lower-income populations rather than becoming treatments available primarily to wealthy patients?
Philanthropy is beginning to address those questions.
The Office of Systems Catalyst, a project of the 1440 Foundation, connects donors with organizations working on psychedelic healthcare implementation, including access for Medicaid and Medicare beneficiaries and underserved communities.
The Psychedelic Education Partnership is tackling another major bottleneck: workforce preparation.
The organization has raised approximately $3.7 million since 2022 and developed a network of faculty fellows spanning 70 universities in 35 states. Its work reaches nursing, medicine, psychology, counseling, social work and public health.
This represents an important evolution.
Funding the discovery of an effective treatment and funding the healthcare system capable of delivering that treatment safely are fundamentally different problems.
Safety Could Become a Major Philanthropic Category
Rapid expansion also creates risks.
The psychedelic field has faced serious questions surrounding practitioner standards, adverse events, inappropriate treatment practices and the safety of unregulated psychedelic use.
Kristin Nash established the William G. Nash Foundation after her son, William, died in 2020 following a crisis while using psilocybin with friends.
Nash and other researchers have proposed that drug developers and major psychedelic philanthropists dedicate approximately 1% of psychedelic research and education spending to safety research and education.
That idea deserves attention.
As psychedelic use expands, safety could become its own significant philanthropic field encompassing adverse-event surveillance, practitioner standards, contraindication research, ethics, crisis-response protocols, public education and harm reduction.
Enthusiasm for psychedelic medicine and rigorous examination of its risks do not have to be opposing positions. A mature field requires both.
Are the Big Foundations Coming Next?
Perhaps the most important unanswered question is what happens when mainstream institutional philanthropy enters psychedelic medicine.
So far, much of the field has been financed by wealthy individuals, family foundations and specialized psychedelic funders. Large conventional foundations have generally been more cautious.
FDA approval could change that calculus.
The evolution of psychedelic funding may ultimately look something like this:
individual philanthropists and family foundations → specialized psychedelic funding networks → government and biotechnology investment → pharmaceutical industry participation → mainstream institutional philanthropy
By that measure, the field appears to be entering one of the final stages of institutionalization.
That makes 2026 through 2028 a potentially important window for psychedelic philanthropy.
The science has gained credibility. Government involvement is increasing. Pharmaceutical capital is arriving. Yet many of the systems required to translate psychedelic medicines into safe, accessible and scalable treatments remain underdeveloped.
Those gaps are precisely where philanthropy can have its greatest leverage.
For the next generation of psychedelic donors, the question may therefore no longer be simply whether psychedelic medicine works.
It may be:
What does society need to build around it if it does?
Source: Ben Gose, “As psychedelics near FDA approval, donors rush to fund the next frontier,” The Chronicle of Philanthropy, September 3, 2026.
